Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 260

Results For "Inc"

6651 News Found

India approves Rs. 10,300 crore for AI Mission
Digitisation | March 08, 2024

India approves Rs. 10,300 crore for AI Mission

The investment will catalyse various components of the IndiaAI Mission


Sakar's oncology unit receives EU GMP approval
Drug Approval | March 07, 2024

Sakar's oncology unit receives EU GMP approval

The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters


Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh
Biotech | March 07, 2024

Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh

India has reached to nearly 6,000 bio-startups from 50 in the past 10 years


Briefs: Zydus, Advanced Enzyme Technologies, Link Pharma Chem and ANVISA
News | March 07, 2024

Briefs: Zydus, Advanced Enzyme Technologies, Link Pharma Chem and ANVISA

ANVISA issues CGMP to Concord Biotech’s Unit I


Govt supports Alchem Synthon with Rs. 8.6 crore loan assistance for chemical production facility
News | March 07, 2024

Govt supports Alchem Synthon with Rs. 8.6 crore loan assistance for chemical production facility

The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities


Strides receives USFDA approval for Gabapentin Tablets
Drug Approval | March 06, 2024

Strides receives USFDA approval for Gabapentin Tablets

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty


Dr. Mandaviya inaugurates Sadhana Nitro Chem’s Para Amino Phenol bulk drug plant
Policy | March 06, 2024

Dr. Mandaviya inaugurates Sadhana Nitro Chem’s Para Amino Phenol bulk drug plant

Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene


Bayer aims to enhance performance and regain strategic flexibility by 2026
News | March 06, 2024

Bayer aims to enhance performance and regain strategic flexibility by 2026

Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis


Bayer strengthens pharma portfolio with new cardiology drug acoramidis
News | March 06, 2024

Bayer strengthens pharma portfolio with new cardiology drug acoramidis

Acquisition of exclusive commercialization rights for European markets


BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends
Clinical Trials | March 06, 2024

BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months